An expert committee (SEC) has recommended to the Drugs Controller General of India the use of Covaxin for children aged 2-18 years.
The recommendations have now been forwarded to the DCGI for final approval.
The Phase 2/3 trials of Covaxin for use in children under 18 years took place in mid-September.
The vaccine manufacturer had submitted the data to the Central Drugs Standard Control Organisation (CDSCO) for its verification.
“After detailed deliberation, the committee recommended grant of market authorisation of the vaccine for the age group of 2 to 18 years for restricted use in emergency situations subject to the certain conditions,” the SEC recommendations mention.
Covaxin will be the second vaccine cleared for use on kids in India.
This comes after Zydus Cadila’s three-dose DNA jab was allowed in August to be used on adults and children over 12.
When it comes to Covid-19, India is slowly turning its focus towards vaccinating children.